Thursday , 18 April 2019
Breaking News
Cadila Healthcare’s arm gets one observation for Ahmedabad plant from USFDA

Cadila Healthcare’s arm gets one observation for Ahmedabad plant from USFDA

The US Food and Drug Administration (USFDA) has conducted a Pre-Approval Inspection (PAI) for Doxorubicin Liposomal, a complex oncological injectable at Alidac Pharmaceuticals, the injectable onco manufacturing facility, located at Pharmez, Ahmedabad from March 18 to 26, 2019. The inspection concluded with one observation.

Alidac Pharmaceuticals is a 100% subsidiary of Cadila Healthcare. The company is addressing these observations and is confident of getting the product approval at the earliest.

Cadila Healthcare is an India-based pharmaceutical company. The company’s subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.



Leave a Reply

Your email address will not be published. Required fields are marked *

*